,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2019-03-04 07:10:00,"Chicago, IL - February 22, 2019 - Zacks Equity Research GW Pharmaceuticals GWPH as the Bull of the Day, Hasbro HAS as the Bear of the Day.",0.24419692158699036,0.030423013493418694,0.7253800630569458,neutral,0.2137739062309265
1,2019-03-04 07:10:00,"In addition, Zacks Equity Research provides analysis on Salesforce CRM , American Express AXP and Intuit INTU .",0.02178962156176567,0.007110446225851774,0.9710999727249146,neutral,0.01467917487025261
2,2019-03-04 07:10:00,"Here is a synopsis of all six stocks:

GW Pharmaceuticals just delivered initial-launch sales numbers for the first FDA-approved cannabis-derived drug, Epidiolex, which was created and tested starting four years ago for the treatment of two rare forms of epilepsy.",0.21481309831142426,0.007104694377630949,0.7780821323394775,neutral,0.20770840346813202
3,2019-03-04 07:10:00,"The company surprised investors and analysts with the launch which achieved $4.7 million in Epidiolex sales just for November and December, far surpassing the consensus of $2.5 million.",0.9414986371994019,0.018824029713869095,0.039677321910858154,positive,0.9226745963096619
4,2019-03-04 07:10:00,"Other key metrics in the press release on February 26...

· First plant-derived cannabinoid pharmaceutical ever approved by FDA and first ever approved medicine in the U.S. for Dravet syndrome

· Approximately 4,500 new patient enrollment forms in first two month selling period

· Over 500 physicians have generated dispensed prescriptions in first two month selling period

· Demand coming from major centers of excellence and local epilepsy clinics

· Pharmacy distribution network expanded from initial 5 specialty pharmacies to over 130 distribution points

· Approximately 900 expanded access program and open label extension patients expected to migrate to commercial product by end of Q2 2019

According to Piper Jaffray analyst Danielle Brill, GW Pharmaceutical metrics indicate a ""hugely successful"" Epidiolex launch.",0.9098958969116211,0.012244535610079765,0.0778595507144928,positive,0.8976513743400574
5,2019-03-04 07:10:00,The analyst noted that Epidiolex revenues of $4.7 million for the first quarter of commercial launch even beat her optimistic call for $3.7 million.,0.9366709589958191,0.03054695390164852,0.03278208523988724,positive,0.9061239957809448
6,2019-03-04 07:10:00,"In her post-earnings research note titled ""Epidiolex Metrics Signify a Hugely Successful Launch,"" Brill noted that Q4 was obviously a shortened quarter with the early November sales launch and including two holiday weeks.",0.043578580021858215,0.8744513392448425,0.08197009563446045,negative,-0.8308727741241455
7,2019-03-04 07:10:00,Refill rates were likely very low due to protracted initial turnaround times.,0.02870810404419899,0.5162762999534607,0.45501554012298584,negative,-0.487568199634552
8,2019-03-04 07:10:00,"The analyst expects to see ""significant"" revenue growth in the coming quarters and she reiterated her Overweight rating on shares as the stock traded 14% higher on 3X the normal volume on Feb 27.",0.9488900899887085,0.018215075135231018,0.032894864678382874,positive,0.9306750297546387
9,2019-03-04 07:10:00,"GW Pharma was founded in the UK in 1998 by two physicians, Geoffrey Guy and Brian Whittle.",0.049351904541254044,0.005997032858431339,0.9446510672569275,neutral,0.04335487261414528
10,2019-03-04 07:10:00,"Their mission right from the start was to research and develop cannabinoid medicines, with particular emphasis on ailments of the central nervous system (CNS).",0.09113059937953949,0.0047327871434390545,0.9041365385055542,neutral,0.08639781177043915
11,2019-03-04 07:10:00,In 2010 they achieved approval in the UK for the first cannabinoid treatment for Multiple Sclerosis.,0.8857403993606567,0.015563382767140865,0.09869622439146042,positive,0.8701770305633545
12,2019-03-04 07:10:00,This long track record of success gave US regulators confidence in the science and R&D of GW.,0.8989988565444946,0.013287190347909927,0.08771390467882156,positive,0.885711669921875
13,2019-03-04 07:10:00,"When the FDA approved Epidiolex in June of 2018 for Dravet syndrome, they called it an ""important scientific advance.""",0.8134472966194153,0.013247199356555939,0.17330540716648102,positive,0.8002001047134399
14,2019-03-04 07:10:00,And this paved the way for the US Drug Enforcement Agency (DEA) to move the drug to the safest level in the controlled substance classification system.,0.885775625705719,0.014319551177322865,0.0999048724770546,positive,0.8714560866355896
15,2019-03-04 07:10:00,This is important because marijuana itself remains a Schedule I drug which means it is classified as having little medicinal value and could be dangerous and/or addictive.,0.016160940751433372,0.11751685291528702,0.8663221597671509,neutral,-0.1013559103012085
16,2019-03-04 07:10:00,"Now, the first approved cannabinoid medicine is seeing sales estimates rise rapidly as other CNS health indications could be served by the GW pipeline.",0.9147090315818787,0.014773843809962273,0.07051713019609451,positive,0.8999351859092712
17,2019-03-04 07:10:00,Some investment bank analysts see sales as high as $500 million for the company in 2020.,0.6424967050552368,0.01432298868894577,0.3431803286075592,positive,0.6281737089157104
18,2019-03-04 07:10:00,"That would represent a 3300% revenue ramp in just 2 years from 2018's $15 million and means the GW pipeline could be poised for ""blockbuster"" status, or potentially worth at least $1 billion in sales.",0.9475419521331787,0.029770582914352417,0.022687360644340515,positive,0.9177713394165039
19,2019-03-04 07:10:00,There are over 100 cannabinoid compounds in the marijuana plant that could be used for medicinal research.,0.07995714992284775,0.009182234294712543,0.9108605980873108,neutral,0.07077491283416748
20,2019-03-04 07:10:00,"In a sense, GW Pharma could be seen as an important trail blazer with its successful approval and launch of Epidiolex.",0.9035030007362366,0.013766090385615826,0.08273091912269592,positive,0.8897368907928467
21,2019-03-04 07:10:00,"In two investor presentations I did for Zacks followers before the GW earnings report, I emphasized this ""trail blazer"" role and also the significance of insurance companies as key partners in the patient-physician-payer alliance.",0.3751758337020874,0.010184353217482567,0.6146398186683655,neutral,0.3649914860725403
22,2019-03-04 07:10:00,"While there are over 20 FDA-approved epilepsy drugs on the market, even the ones for orphan conditions like Dravet and Lennox-Gastaut syndromes, the two that Epidiolex can treat, don't work for every family.",0.029714079573750496,0.4382912218570709,0.5319947600364685,neutral,-0.4085771441459656
23,2019-03-04 07:10:00,"So for patients and physicians to have the flexibility from payers to try the new cannabinoid treatments is a tremendous opportunity for all, including GW.",0.8477246761322021,0.013467131182551384,0.13880819082260132,positive,0.8342575430870056
24,2019-03-04 07:10:00,The other larger issue I've raised is that these stakeholders don't want to look for medical solutions in the wild west of CBD products now available on the internet without a prescription.,0.03395717963576317,0.26382601261138916,0.7022168636322021,neutral,-0.2298688292503357
25,2019-03-04 07:10:00,"For young children with specific diseases, there is ""no supplement"" for the tested and regulated efficacy, safety, and quality of a doctor-prescribed dosage.",0.015158840455114841,0.01623130589723587,0.9686098694801331,neutral,-0.001072465442121029
26,2019-03-04 07:10:00,"To wit, when Justin Gover, the CEO of GW Pharmaceuticals, was on CNBC's Mad Money after the company report he explained to host Jim Cramer that ""Epidiolex is different from other CBD options.""",0.09071245044469833,0.11430782079696655,0.7949796915054321,neutral,-0.02359537035226822
27,2019-03-04 07:10:00,"""We do real science and produce medicines with safety and efficacy... Epidiolex is not marijuana, it is CBD approved by the FDA.",0.1250392645597458,0.0054954225197434425,0.8694652915000916,neutral,0.11954384297132492
28,2019-03-04 07:10:00,"We're only reporting two months of sales, so some caution is warranted... we're at the beginning of the journey with Epidiolex and looking at other uses for it.""",0.22042784094810486,0.016182895749807358,0.7633892297744751,neutral,0.2042449414730072
29,2019-03-04 07:10:00,"After the report, i-bank Stifel Nicolaus raised their sales estimate for this year from $122 million to $136.5 million.",0.8660004138946533,0.019890056923031807,0.11410953849554062,positive,0.8461103439331055
30,2019-03-04 07:10:00,And they raised their PT from $179 to $191.,0.8776819109916687,0.015940405428409576,0.1063777357339859,positive,0.8617414832115173
31,2019-03-04 07:10:00,I was telling long-term healthcare investors 2 weeks ago to consider nibbling on some shares under $150.,0.04513080045580864,0.035964470356702805,0.9189047813415527,neutral,0.009166330099105835
32,2019-03-04 07:10:00,I wish I had myself.,0.1461704969406128,0.10864923149347305,0.7451803088188171,neutral,0.03752126544713974
33,2019-03-04 07:10:00,This will be one to accumulate on pullbacks as the science and the sales have proven worthy of a blockbuster trajectory.,0.8645965456962585,0.019129127264022827,0.11627433449029922,positive,0.8454674482345581
34,2019-03-04 07:10:00,Hasbro is a Zacks Rank #5 (Strong Sell) and in this Bear of the Day article we will take a look at why that is the case.,0.07132674008607864,0.014673221856355667,0.9140000343322754,neutral,0.05665351822972298
35,2019-03-04 07:10:00,The first thing I do when looking at a Bear is to review who they are and what they do.,0.018895654007792473,0.014099158346652985,0.9670052528381348,neutral,0.004796495661139488
36,2019-03-04 07:10:00,"Hasbro, Inc. is a global play and entertainment company committed to creating the World's Best Play Experiences.",0.6871400475502014,0.011322456412017345,0.3015374541282654,positive,0.675817608833313
37,2019-03-04 07:10:00,"From toys and games to television, movies, digital gaming and consumer products, Hasbro offers a variety of ways for audiences to experience its iconic brands, including NERF, MY LITTLE PONY, TRANSFORMERS, PLAY-DOH, MONOPOLY, LITTLEST PET SHOP and MAGIC: THE GATHERING, as well as premier partner brands.",0.27897289395332336,0.007616346701979637,0.7134107947349548,neutral,0.2713565528392792
38,2019-03-04 07:10:00,"Through Hasbro Studios and its film labels, Allspark Pictures and Allspark Animation, the Company is building its brands globally through great storytelling and content on all screens.",0.8589146733283997,0.013304594904184341,0.1277807354927063,positive,0.8456100821495056
39,2019-03-04 07:10:00,Hasbro is committed to making the world a better place for children and their families through corporate social responsibility and philanthropy.,0.604096531867981,0.012662330642342567,0.38324105739593506,positive,0.5914341807365417
40,2019-03-04 07:10:00,I see a poor earnings history with the company missing the Zacks Consensus Estimate in three of the last four reports.,0.01907527633011341,0.9608417749404907,0.020083017647266388,negative,-0.9417665004730225
41,2019-03-04 07:10:00,"The most recent miss was a 20% negative earnings surprise and before that, there was a 13.8% negative earnings surprise.",0.018878474831581116,0.9508386850357056,0.030282815918326378,negative,-0.9319602251052856
42,2019-03-04 07:10:00,This is the main reason a stock falls to the lowest Zacks Rank.,0.0664534643292427,0.6123723387718201,0.3211742043495178,negative,-0.545918881893158
43,2019-03-04 07:10:00,I see the current quarter moving from a gain of 18 cents 30 days ago to a loss of two cents.,0.6388858556747437,0.27391815185546875,0.08719602227210999,positive,0.3649677038192749
44,2019-03-04 07:10:00,That is a huge shift lower.,0.16443584859371185,0.35791510343551636,0.4776490330696106,neutral,-0.1934792548418045
45,2019-03-04 07:10:00,"The 2019 number has also slid, from $5.14 to $4.49.",0.01921440102159977,0.9609769582748413,0.019808655604720116,negative,-0.9417625665664673
46,2019-03-04 07:10:00,"When estimates fall, the Zacks Rank tends to follow.",0.029031192883849144,0.7476587295532227,0.22331009805202484,negative,-0.7186275124549866
47,2019-03-04 07:10:00,"Salesforce (CRM) Looks Like a Buy Ahead of Earnings

Salesforce stock hit a new high in morning trading Friday.",0.929613471031189,0.030226310715079308,0.040160249918699265,positive,0.8993871808052063
48,2019-03-04 07:10:00,"Now, with the software-as-a-service firm set to report its Q4 financial results after the closing bell Monday, let's see why Salesforce stock looks like a strong buy heading into earnings.",0.6653903722763062,0.03441740199923515,0.3001922369003296,positive,0.6309729814529419
49,2019-03-04 07:10:00,"Salesforce offers its business clients a wide range of cloud-based platforms to help them run sales, marketing, e-commerce, analytics, and much more.",0.12265103310346603,0.0049820998683571815,0.8723668456077576,neutral,0.11766893416643143
50,2019-03-04 07:10:00,"The San Francisco-based firm looks poised to grow for years to come because its customer relationship management offerings have become essential to many companies and would otherwise require a large amount of in-house talent, infrastructure, and maintenance.",0.7780947685241699,0.011473018676042557,0.21043218672275543,positive,0.7666217684745789
51,2019-03-04 07:10:00,"Salesforce's clients include American Express, Intuit, the U.S. Department of Agriculture, and more than 150,000 other firms and agencies.",0.03040049597620964,0.0053878300823271275,0.9642117023468018,neutral,0.0250126663595438
52,2019-03-04 07:10:00,"Marc Benioff's company also has introduced new wrinkles to its Einstein artificial intelligence platform, such the ability to conversationally update tasks.",0.5566772818565369,0.0162733793258667,0.42704933881759644,positive,0.5404039025306702
53,2019-03-04 07:10:00,And Salesforce completed a $6.5 billion acquisition of MuleSoft-which helps link disparate applications-last year.,0.6885354518890381,0.011898424476385117,0.2995660901069641,positive,0.6766370534896851
54,2019-03-04 07:10:00,"Overall, Salesforce offers software and web-based services that allow companies to operate in today's connected age, which is hardly cyclical or trendy.",0.09281779080629349,0.0058450717478990555,0.9013371467590332,neutral,0.08697272092103958
55,2019-03-04 07:10:00,"""Companies across every industry, in every geography have a mandate to digitally transform their businesses and are turning to Salesforce as a strategic partner,"" co-CEO Keith Block said in prepared statements last quarter.",0.742761492729187,0.011024712584912777,0.24621376395225525,positive,0.7317367792129517
56,2019-03-04 07:10:00,"Salesforce's Q4 fiscal 2019 revenues are projected to climb 24.9% to reach $3.56 billion, based on our current Zacks Consensus Estimate.",0.9468380212783813,0.017794445157051086,0.035367511212825775,positive,0.9290435910224915
57,2019-03-04 07:10:00,"This would fall just short of Q3's 26% top-line surge, but beat the year-ago period's 24% expansion.",0.5905893445014954,0.3774547874927521,0.03195581212639809,positive,0.2131345570087433
58,2019-03-04 07:10:00,"Meanwhile, CRM's full-year revenues are projected to climb over 26% to hit $13.24 billion, which would top fiscal 2018's 25% climb.",0.9503011107444763,0.019057536497712135,0.03064141608774662,positive,0.9312435984611511
59,2019-03-04 07:10:00,"More specifically, our NFM estimate calls for the firm's quarterly subscription and support revenue to climb over 25% from $2.66 billion in the year-ago quarter to touch $3.33 billion.",0.9576767086982727,0.0182061567902565,0.024117156863212585,positive,0.9394705295562744
60,2019-03-04 07:10:00,"CRM's much smaller, professional services and other unit is expected to jump roughly 19.3% and hit $233.9 million.",0.939460813999176,0.021415024995803833,0.03912418708205223,positive,0.9180457592010498
61,2019-03-04 07:10:00,"At the bottom end of the income statement, Salesforce's adjusted fourth-quarter EPS figure is projected to soar 60% to come in at $0.56 per share.",0.4203818142414093,0.17780035734176636,0.4018178880214691,positive,0.24258145689964294
62,2019-03-04 07:10:00,"In Q3, the company's adjusted earnings of $0.61 a share beat our $0.50 EPS estimate that would have marked a 28% jump.",0.9512234926223755,0.028877291828393936,0.019899167120456696,positive,0.9223461747169495
63,2019-03-04 07:10:00,Salesforce's adjusted full-year earnings are expected to skyrocket by over 93%.,0.9172720313072205,0.037552740424871445,0.04517518728971481,positive,0.8797193169593811
64,2019-03-04 07:10:00,"Plus, CRM's fiscal 2019 earnings estimate has come up by $0.07 over the last 90 days.",0.9485322833061218,0.022620953619480133,0.02884676307439804,positive,0.9259113073348999
65,2019-03-04 07:10:00,The company's fiscal 2020 EPS picture has also turned more positive during this stretch.,0.9242416024208069,0.017296407371759415,0.05846197530627251,positive,0.9069451689720154
66,2019-03-04 07:10:00,"Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions.",0.023836323991417885,0.005520980339497328,0.9706427454948425,neutral,0.01831534318625927
67,2019-03-04 07:10:00,"Zacks is providing information on this resource to you subject to the Zacks ""Terms and Conditions of Service"" disclaimer.",0.0142265185713768,0.008723904378712177,0.9770495891571045,neutral,0.005502614192664623
68,2019-03-04 07:10:00,www.zacks.com/disclaimer .,0.03363189846277237,0.05275096744298935,0.9136171340942383,neutral,-0.01911906898021698
69,2019-03-04 07:10:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
70,2019-03-04 07:10:00,"Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.01234789565205574,0.011841878294944763,0.975810170173645,neutral,0.0005060173571109772
71,2019-03-04 07:10:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
72,2019-03-04 07:10:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
73,2019-03-04 07:10:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
74,2019-03-04 07:10:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
75,2019-03-04 07:10:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
76,2019-03-04 07:10:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
77,2019-03-04 07:10:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
78,2019-03-04 07:10:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
79,2019-03-04 07:10:00,Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01078665629029274,0.015373211354017258,0.9738401174545288,neutral,-0.004586555063724518
80,2019-03-04 07:10:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
81,2019-03-04 07:10:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
82,2019-03-04 07:10:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
83,2019-03-04 07:10:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
